Dose every patient from their own molecular imaging.
YSOTOPE reads each patient's PET scan and builds a personal radiopharmaceutical PK model so oncologists can prescribe the absorbed dose that will work, not a population average.
Population averages leave patients at risk
Published dosimetry literature documents a wide range of variability in absorbed dose across patients receiving identical administered activities. Standard protocols cannot close this gap.
Studies show up to 3.5-fold variation in absorbed tumor dose across patients given the same administered activity, based on published theranostics dosimetry literature.
Estimates from dosimetry research suggest a substantial fraction of patients receive absorbed doses outside the therapeutic window under population-average protocols.
Most centers prescribe activity from a single pre-therapy scan. Patient-specific PK modeling requires serial imaging data that existing workflows rarely collect.
From PET scan to personalized dose in one workflow
YSOTOPE integrates into existing nuclear medicine infrastructure, reads the patient's scan data, and returns a dose recommendation grounded in that individual's pharmacokinetics.
Upload PET or SPECT scan
DICOM files transfer directly from your PACS. YSOTOPE accepts serial time-point imaging across the uptake and clearance window.
AI builds a patient-specific PK model
Organ-level tracer quantification drives a two-compartment pharmacokinetic model fitted to that individual's uptake and washout kinetics.
Receive optimized dose recommendation
The model outputs an absorbed dose estimate per organ alongside a recommended administered activity, ready for oncologist review before prescribing.
From our early-access pilot program
Data from our pilot program covering 74 patient scans across 3 participating oncology centres in Spain, Germany, and the Netherlands.
Reduction in individual patient dose deviation vs population-average baseline, measured across pilot scans.
Serial PET and SPECT datasets analysed across Lu-177 and I-131 theranostics programmes in our pilot centres.
Nuclear medicine and nuclear oncology departments participating in YSOTOPE's early-access programme across Europe.
Oncologists on patient-specific dosing
The shift from population-based activity to absorbed dose grounded in the patient's own scan data changes the conversation we can have with patients about their therapy. YSOTOPE made that transition straightforward to implement within our existing workflow.
Our team was skeptical that adding a PK modeling step would fit our session schedule. The turnaround time is fast enough that we can have the dose recommendation before the prescribing decision. That was the deciding factor for us.
Built by theranostics specialists
Dosimetry scientists, computational imaging researchers, and clinical oncologists building the precision dosing platform nuclear medicine has been waiting for.
Marina Sole
Background in clinical translation and oncology commercialisation. Marina's work sits at the boundary between clinical practice and product development in AI medical systems, with a focus on getting dosimetry tools to the point where oncologists actually use them.
Dr. Andrei Vascu
Background in computational imaging and dose-optimisation algorithm design. Andrei's work spans quantitative molecular imaging systems and the signal-processing steps that make organ-level PK model fitting tractable at clinical throughput.
Dr. Fatima Okonkwo
Nuclear medicine specialist and precision oncology researcher. Conducted patient dosimetry studies across multiple European oncology centers and contributed to clinical protocol development for targeted radionuclide therapy programs.
Join oncology clinics already dosing with precision.
We are accepting a limited cohort of nuclear medicine departments for our 2026 early-access pilot program. Participating centers receive dedicated onboarding support and direct access to our dosimetry team.
Limited pilot capacity. Response within 3 business days.